These authors contributed equally to this work.
Article first published online: 16 DEC 2011
Copyright © 2011 American Association for the Study of Liver Diseases
Volume 55, Issue 2, pages 384–394, February 2012
How to Cite
Bochud, P.-Y., Bibert, S., Kutalik, Z., Patin, E., Guergnon, J., Nalpas, B., Goossens, N., Kuske, L., Müllhaupt, B., Gerlach, T., Heim, M. H., Moradpour, D., Cerny, A., Malinverni, R., Regenass, S., Dollenmaier, G., Hirsch, H., Martinetti, G., Gorgiewski, M., Bourlière, M., Poynard, T., Theodorou, I., Abel, L., Pol, S., Dufour, J.-F., Negro, F. and on behalf of the Swiss Hepatitis C Cohort Study Group the ANRS HC EP 26 Genoscan Study Group (2012), IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology, 55: 384–394. doi: 10.1002/hep.24678
Potential conflict of interest: Dr. Poynard owns stock in Biopredictive. He also consults for and is on the speakers' bureau of Merck. Dr. Pol consults for, advises, and is on the speakers' bureau of Boehringer Ingleheim, Abbott, and GlaxoSmithKline. He consults for, advises, is on the speakers' bureau of, and received grants from Roche, Gilead, Bristol-Myers Squibb, and MSD.
Members of the Swiss Hepatitis C Cohort Study Group: Francesco Negro (Geneva, Chairman), Antoine Hadengue (Geneva, Chairman of Scientific Committee), Laurent Kaiser, Laura Rubbia-Brandt (Geneva); Darius Moradpour, Cristina Cellerai (Lausanne); Martin Rickenbach (Lausanne Data Center); Andreas Cerny, Gladys Martinetti (Lugano); Jean-François Dufour, Meri Gorgievski, Virginie Masserey Spicher (Berne); Markus Heim, Hans Hirsch (Basel); Beat Müllhaupt, Beat Helbling, Stephan Regenass (Zurich); Raffaele Malinverni (Neuchatel); David Semela, Guenter Dollenmaier (St Gallen); Gieri Cathomas (Liestal).
- Issue published online: 27 JAN 2012
- Article first published online: 16 DEC 2011
- Accepted manuscript online: 19 SEP 2011 09:04AM EST
- Manuscript Accepted: 30 AUG 2011
- Manuscript Received: 26 JUL 2011
- Swiss National Science Foundation. Grant Number: 3347C0-108782/1
- Swiss Federal Office for Education and Sciences (03.0599)
- European Commission
- VIRGIL Network of Excellence on Antiviral Drug Resistance
- National Agency for Research on AIDS and Viral Hepatitis (ANRS)
- Swiss National Science Foundation. Grant Number: 314730-130498
- the Swiss National Foundation. Grant Number: 32003B-127613
- Leenaards Foundation
- Santos-Suarez Foundation
- 22IL28B polymorphisms significantly correlate with IFN antiviral effectiveness already on first day of pegylated interferon-α/ribavirin therapy of chronic HCV infection. J Hepatol 2011 [Epub ahead of print]., , , , , , et al.
- 30Genome-wide association study identifies IL28B polymorphisms to be associated with baseline ALT and hepatic necroinflammatory activity in chronic hepatitis C patients enrolled in the IDEAL study. HEPATOLOGY 2010; 52 ( Suppl): 1221A., , , , , , et al.
- 31IL28B genotype is not associated with advanced hepatic fibrosis in chronic hepatitis C patients enrolled in the IDEAL study. HEPATOLOGY 2010; 52( Suppl): 437A., , , , , , et al.
- 34Intrahepatic and peripheral blood virus-specific cytotoxic T lymphocyte activity is associated with a response to combination IFN-alpha and ribavirin treatment among patients with chronic hepatitis C virus infection. J Viral Hepat 2005; 12: 125-129., , , .
- 46Association between IL28B gene variation and development of hepatocellular carcinoma after interferon therapy in patients with chronic hepatitis C. J Hepatol 2011; 54( Suppl): S37., , , , , , et al.